Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), accounting for 85% of liver cancer cases, continues to be the third leading cause of cancer-related deaths worldwide. Although various forms of chemotherapy and immunotherapy have been investigated in clinics, patients continue to suffer from high toxicity and undesir...

Full description

Saved in:
Bibliographic Details
Main Author: Basu A.
Other Authors: Mahidol University
Format: Review
Published: 2023
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/87933
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
id th-mahidol.87933
record_format dspace
spelling th-mahidol.879332023-07-18T01:03:28Z Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma Basu A. Mahidol University Pharmacology, Toxicology and Pharmaceutics Hepatocellular carcinoma (HCC), accounting for 85% of liver cancer cases, continues to be the third leading cause of cancer-related deaths worldwide. Although various forms of chemotherapy and immunotherapy have been investigated in clinics, patients continue to suffer from high toxicity and undesirable side effects. Medicinal plants contain novel critical bioactives that can target multimodal oncogenic pathways; however, their clinical translation is often challenged due to poor aqueous solubility, low cellular uptake, and poor bioavailability. Nanoparticle-based drug delivery presents great opportunities in HCC therapy by increasing selectivity and transferring sufficient doses of bioactives to tumor areas with minimal damage to adjacent healthy cells. In fact, many phytochemicals encapsulated in FDA-approved nanocarriers have demonstrated the ability to modulate the tumor microenvironment. In this review, information about the mechanisms of promising plant bioactives against HCC is discussed and compared. Their benefits and risks as future nanotherapeutics are underscored. Nanocarriers that have been employed to encapsulate both pure bioactives and crude extracts for application in various HCC models are examined and compared. Finally, the current limitations in nanocarrier design, challenges related to the HCC microenvironment, and future opportunities are also discussed for the clinical translation of plant-based nanomedicines from bench to bedside. 2023-07-17T18:03:28Z 2023-07-17T18:03:28Z 2023-06-01 Review Pharmaceutics Vol.15 No.6 (2023) 10.3390/pharmaceutics15061611 19994923 2-s2.0-85163790548 https://repository.li.mahidol.ac.th/handle/123456789/87933 SCOPUS
institution Mahidol University
building Mahidol University Library
continent Asia
country Thailand
Thailand
content_provider Mahidol University Library
collection Mahidol University Institutional Repository
topic Pharmacology, Toxicology and Pharmaceutics
spellingShingle Pharmacology, Toxicology and Pharmaceutics
Basu A.
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
description Hepatocellular carcinoma (HCC), accounting for 85% of liver cancer cases, continues to be the third leading cause of cancer-related deaths worldwide. Although various forms of chemotherapy and immunotherapy have been investigated in clinics, patients continue to suffer from high toxicity and undesirable side effects. Medicinal plants contain novel critical bioactives that can target multimodal oncogenic pathways; however, their clinical translation is often challenged due to poor aqueous solubility, low cellular uptake, and poor bioavailability. Nanoparticle-based drug delivery presents great opportunities in HCC therapy by increasing selectivity and transferring sufficient doses of bioactives to tumor areas with minimal damage to adjacent healthy cells. In fact, many phytochemicals encapsulated in FDA-approved nanocarriers have demonstrated the ability to modulate the tumor microenvironment. In this review, information about the mechanisms of promising plant bioactives against HCC is discussed and compared. Their benefits and risks as future nanotherapeutics are underscored. Nanocarriers that have been employed to encapsulate both pure bioactives and crude extracts for application in various HCC models are examined and compared. Finally, the current limitations in nanocarrier design, challenges related to the HCC microenvironment, and future opportunities are also discussed for the clinical translation of plant-based nanomedicines from bench to bedside.
author2 Mahidol University
author_facet Mahidol University
Basu A.
format Review
author Basu A.
author_sort Basu A.
title Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
title_short Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
title_full Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
title_fullStr Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
title_full_unstemmed Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
title_sort critical review in designing plant-based anticancer nanoparticles against hepatocellular carcinoma
publishDate 2023
url https://repository.li.mahidol.ac.th/handle/123456789/87933
_version_ 1781416150306914304